Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Schuessler, Andrea ^a   Walker, David G ^b   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b WESLEY HOSPITAL   (Australia)

Author keywords

Adoptive transfer; Checkpoint modulators; Cytomegalovirus; Glioblastoma multiforme; Immunotherapy; T cell

Indexed keywords

BASILIXIMAB; BEVACIZUMAB; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOMEGALOVIRUS ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN BCL 6; RANTES; TEMOZOLOMIDE; TETANUS TOXOID; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VALGANCICLOVIR; VASCULOTROPIN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANGIOGENESIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CYTOMEGALOVIRUS; DOWN REGULATION; GLIOBLASTOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; VACCINATION;

EID: 84907812670     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00275     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352(10):987-96. doi: 10.1056/NEJMoa043330
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10(5):459-66. doi:10.1016/S1470-2045(09)70025-7
3. Reardon DA, Herndon JE II, Peters KB, Desjardins A, Coan A, Lou E, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer (2012) 107(9):1481-7. doi:10.1038/bjc.2012.415
4. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 12(6):597-615. doi:10.1586/erv.13.41
5. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 370(8):709-22. doi:10.1056/NEJMoa1308345
6. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 370(8):699-708. doi:10.1056/NEJMoa1308573
7. ClinicalTrials.gov. Available from: www.clinicaltrials.gov
8. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 62(12):3347-50.
9. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol (2006) 12(2):90-9. doi:10.1080/13550280600654573
10. Sabatier J, Uro-Coste E, Pommepuy I, Labrousse F, Allart S, Tremoulet M, et al. Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer (2005) 92(4):747-50. doi:10.1038/sj.bjc.6602339
11. Lau SK, Chen YY, Chen WG, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol (2005) 18(6):838-43. doi:10.1038/modpathol.3800352
12. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol (2011) 103(2):231-8. doi:10.1007/s11060-010-0383-6
13. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2008) 10(1):10-8. doi:10.1215/15228517-2007-035
14. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 116(1):79-86. doi:10.1007/s00401-008-0359-1
15. Bhattacharjee B, Renzette N, Kowalik TF. Genetic analysis of cytomegalovirus in malignant gliomas. J Virol (2012) 86(12):6815-24. doi:10.1128/JVI.00015-12
16. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol (2012) 86(2):854-64. doi:10.1128/JVI.06097-11
17. Cimino PJ, Zhao G, Wang D, Sehn JK, Lewis JS Jr, Duncavage EJ. Detection of viral pathogens in high grade gliomas from unmapped next-generation sequencing data. Exp Mol Pathol (2014) 96(3):310-5. doi:10.1016/j.yexmp.2014.03.010
18. Cosset E, Petty TJ, Dutoit V, Cordey S, Padioleau I, Otten-Hernandez P, et al. Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response. Int J Cancer (2013) 135(6):1381-9. doi:10.1002/ijc.28670
19. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 359(5):539-41. doi:10.1056/NEJMc0804818
20. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 20(10):2684-94. doi:10.1158/1078-0432.CCR-13-3268
21. Noriega V, Redmann V, Gardner T, Tortorella D. Diverse immune evasion strategies by human cytomegalovirus. Immunol Res (2012) 54(1-3):140-51. doi:10.1007/s12026-012-8304-8
22. Smith C, Khanna R. Immune regulation of human herpesviruses and its implications for human transplantation. Am J Transplant (2013) 13(Suppl 3):9-23. doi:10.1111/ajt.12005
23. Maussang D, Langemeijer E, Fitzsimons CP, Stigter-van Walsum M, Dijkman R, Borg MK, et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res (2009) 69(7):2861-9. doi:10.1158/0008-5472.CAN-08-2487
24. Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal (2010) 3(133):ra58. doi:10.1126/scisignal.2001180
25. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res (2011) 157(2):193-203. doi:10.1016/j.virusres.2010.10.026
26. Soroceanu L, Matlaf L, Bezrookove V, Harkins L, Martinez R, Greene M, et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res (2011) 71(21):6643-53. doi:10.1158/0008-5472.CAN-11-0744
27. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Straat K, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol (2013) 57(1):36-42. doi:10.1016/j.jcv.2012.12.018
28. Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J, et al. Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival - a case-control study. Herpesviridae (2012) 3:3. doi:10.1186/2042-4280-3-3
29. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med (2013) 369(10):985-6. doi:10.1056/NEJMc1302145
30. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer (2013) 133(5):1204-13. doi:10.1002/ijc.28111
31. Cobbs CS. Does valganciclovir have a role in glioblastoma therapy? Neuro Oncol (2014) 16(3):330-1. doi:10.1093/neuonc/nou009
32. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol (2012) 90(9):872-80. doi:10.1038/icb.2012.19
33. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 35(2):159-68. doi:10.1097/CJI.0b013e318247642f
34. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood (2011) 118(11):3003-12. doi:10.1182/blood-2011-02-334565P
35. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res (2014) 74(13):3466-76. doi:10.1158/0008-5472.CAN-14-0296
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74.doi:10.1016/j.cell.2011.02.013
37. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol (2009) 11(4):394-402. doi:10.1215/15228517-2008-104
38. Liu Y, Carlsson R, Ambjorn M, Hasan M, Badn W, Darabi A, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci (2013) 33(35):14231-45. doi:10.1523/JNEUROSCI.5812-12.2013